Figures computed from official regulatory filings — .
Analysttarget 1 USD (+280%) · consensus 3/5 · 0 buy · 4 hold · 0 sell
Ownershipinsiders 0.37% · institutions 31.05% · short 6.1% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Vistagen Therapeutics, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder. It also develops refisolone, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders; PH15, an investigational pherine nasal spray, which is in Phase IIa clinical trial for the treatment to improve cognitive impairment caused by mental fatigue disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial to treat loss of appetite associated with chronic disorders, such as cancer cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
12 buys3 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Williamson Douglas J | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Singh Shawn | Award | $7.1K | SEC |
| Tressler Nick B. | Award | $2.2K | SEC |
| Adler Reid G. | Award | $7.1K | SEC |
| Angelov Angel S | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Adler Reid G. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Adler Reid G. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Cote Elissa S. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Tressler Nick B. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Prince Joshua S. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Singh Shawn | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Prince Joshua S. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Singh Shawn | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Prince Joshua S. | Award | $2.5K | SEC |
| Tressler Nick B. | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Edick Paul Rtrack record | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| FitzPatrick Margaret M | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| SAXE JON Strack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Cunningham Ann Michelle | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Curley Joanne | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Rotunno Mary L. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Singh Shawn | Award | $12.8K | SEC |
| Anderson Cynthia Lynn | Award | $11.2K | SEC |
| Adler Reid G. | Award | $12.8K | SEC |
| Prince Joshua S. | Award | $8.3K | SEC |